Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Rhea-AI Summary

Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, with an audio replay accessible for 90 days.

News Market Reaction

+5.13%

1 alert

+5.13% News Effect

On the day this news was published, VRNA gained 5.13%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and ask to join the Verona Pharma call:

• +1-833-816-1396 for callers in the United States
• +1-412-317-0489 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-312-523-5016 tbcverona@tenbridgecommunications.com
Leslie Humbel

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre^TM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

When will Verona Pharma (VRNA) report its Q2 2024 financial results?

Verona Pharma (VRNA) will report its second quarter 2024 financial results on Thursday, August 8, 2024.

What time is Verona Pharma's (VRNA) Q2 2024 earnings call scheduled for?

Verona Pharma's (VRNA) Q2 2024 earnings call is scheduled for 9:00 a.m. EDT / 2:00 p.m. BST on August 8, 2024.

How can investors participate in Verona Pharma's (VRNA) Q2 2024 earnings call?

Investors can participate in Verona Pharma's (VRNA) Q2 2024 earnings call by dialing +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and asking to join the Verona Pharma call.

Where can I find the webcast for Verona Pharma's (VRNA) Q2 2024 earnings call?

The webcast for Verona Pharma's (VRNA) Q2 2024 earnings call will be available on the Events and Presentations link on the Investors page of the company's website, www.veronapharma.com.